NLRP3 and rheumatoid arthritis: The growing appreciation of the NLRP3 inflammasome activation and bioactive IL‐1β release in acute gouty inflammation or in the more chronic rheumatoid arthritis has prompted studies of agents blocking the IL‐1β receptor or soluble IL‐1β (canakinumab, rilonacept, and anakinra).